# multiple system atrophy FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/multiple-system-atrophy

> 8 upcoming FDA catalysts in multiple system atrophy: foralumab nasal (TLSA) on April 2027 (primary completion); foralumab nasal (TLSA) on Apr to Jul 2027 (topline data readout); TEV-56286 (TEVA) on Sep to Dec 2027 (topline data readout); TEV-56286 (TEVA) on September 2027 (primary completion); and 4 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| July 28, 2024 | [ATH434 topline data readout](https://sec-api.dev/pdufa/ath434) | ATHE | multiple system atrophy | completed, positive | "- 28 July 2024: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced positive topline data from the ATH434-202 open-label Phase 2 clinical trial in individuals with multiple system atrophy (MSA)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1131343/000121390025067901/ea025038601ex99-1_alterity.htm)) |
| July 28, 2025 | [TAK-341 primary completion](https://sec-api.dev/pdufa/tak-341) | TAK | Multiple System Atrophy | completed | "NCT05526391 (A Study of TAK-341 in Treatment of Multiple System Atrophy): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-28 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-06-02." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05526391)) |
| June 2, 2026 | [TAK-341 topline data readout](https://sec-api.dev/pdufa/tak-341) | TAK | Multiple System Atrophy | completed | "NCT05526391 (A Study of TAK-341 in Treatment of Multiple System Atrophy): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-28 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-06-02." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05526391?tab=results)) |
| April 2027 | [Foralumab nasal primary completion](https://sec-api.dev/pdufa/foralumab-nasal) | TLSA | Multiple System Atrophy | scheduled | "NCT06868628 (A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-04-01 (ESTIMATED); Lead Sponsor Tiziana Life Sciences LTD." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06868628)) |
| Apr to Jul 2027 | [Foralumab nasal topline data readout](https://sec-api.dev/pdufa/foralumab-nasal) | TLSA | Multiple System Atrophy | scheduled | "NCT06868628 (A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-04-01 (ESTIMATED); Lead Sponsor Tiziana Life Sciences LTD." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06868628)) |
| Sep to Dec 2027 | [TEV-56286 topline data readout](https://sec-api.dev/pdufa/tev-56286) | TEVA | Multiple System Atrophy | scheduled | "NCT06568237 (A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-09-15 (ESTIMATED); Lead Sponsor Teva Branded Pharmaceutical Products R&D LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06568237)) |
| September 2027 | [TEV-56286 primary completion](https://sec-api.dev/pdufa/tev-56286) | TEVA | Multiple System Atrophy | scheduled | "NCT06568237 (A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-09-15 (ESTIMATED); Lead Sponsor Teva Branded Pharmaceutical Products R&D LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06568237)) |
| May to Aug 2029 | [Emrusolmin topline data readout](https://sec-api.dev/pdufa/emrusolmin) | TEVA | Multiple System Atrophy | scheduled | "NCT07197866 (An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-05-03 (ESTIMATED); Lead Sponsor Teva Branded Pharmaceutical Products R&D LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07197866)) |
| May 2029 | [Emrusolmin primary completion](https://sec-api.dev/pdufa/emrusolmin) | TEVA | Multiple System Atrophy | scheduled | "NCT07197866 (An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-05-03 (ESTIMATED); Lead Sponsor Teva Branded Pharmaceutical Products R&D LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07197866)) |
| July 2029 | [ATH434 primary completion](https://sec-api.dev/pdufa/ath434) | ATHE | Multiple System Atrophy | scheduled | "NCT07729852 (Open-Label Access to ATH434 for Patients Who Completed Study ATH434-201 in France): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2029-07 (ESTIMATED); Lead Sponsor Alterity Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07729852)) |
| Jul to Oct 2029 | [ATH434 topline data readout](https://sec-api.dev/pdufa/ath434) | ATHE | Multiple System Atrophy | scheduled | "NCT07729852 (Open-Label Access to ATH434 for Patients Who Completed Study ATH434-201 in France): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2029-07 (ESTIMATED); Lead Sponsor Alterity Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07729852)) |

## Drugs

- [ATH434](https://sec-api.dev/pdufa/ath434) (ATHE)
- [TAK-341](https://sec-api.dev/pdufa/tak-341) (TAK)
- [Foralumab nasal](https://sec-api.dev/pdufa/foralumab-nasal) (TLSA)
- [TEV-56286](https://sec-api.dev/pdufa/tev-56286) (TEVA)
- [Emrusolmin](https://sec-api.dev/pdufa/emrusolmin) (TEVA)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/multiple-system-atrophy.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "multiple system atrophy FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/multiple-system-atrophy

```bibtex
@misc{secapidev_indications_multiple_system_atrophy_20261116,
  title        = {multiple system atrophy FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/multiple-system-atrophy}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_multiple_system_atrophy_20261116","title":"multiple system atrophy FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/multiple-system-atrophy","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
